Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.
- DOI
- 10.1016/j.jtocrr.2025.100909
- Published
- 2025 Dec
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2025.100909,
title = {Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.},
author = {Landi L and Chiari R and Tiseo M and Metro G and de Marinis F and Delmonte A and Novello S and Cortinovis DL and Galetta D and Bonanno L and Gridelli C and Morabito A and Grossi F and Torchia A and Giannarelli D and Borra G and Mazzoni F and Pilotto S and Cappuzzo F},
year = {2025},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2025.100909},
url = {https://doi.org/10.1016/j.jtocrr.2025.100909}
}RIS
TY - JOUR TI - Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial. AU - Landi L AU - Chiari R AU - Tiseo M AU - Metro G AU - de Marinis F AU - Delmonte A AU - Novello S AU - Cortinovis DL AU - Galetta D AU - Bonanno L AU - Gridelli C AU - Morabito A AU - Grossi F AU - Torchia A AU - Giannarelli D AU - Borra G AU - Mazzoni F AU - Pilotto S AU - Cappuzzo F PY - 2025 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2025.100909 UR - https://doi.org/10.1016/j.jtocrr.2025.100909 ER -
APA
L, L., R, C., M, T., G, M., F, D. M., A, D., S, N., DL, C., D, G., L, B., C, G., A, M., F, G., A, T., D, G., G, B., F, M., S, P., & F, C. (2025). Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2025.100909
Source records
- pubmed · retrieved 2026-09-26T06:28:14.875Z
- europe-pmc · retrieved 2026-09-26T06:28:14.875Z
- doaj · retrieved 2026-09-26T06:28:14.857Z